ES2548442T3 - Reovirus que tienen secuencias modificadas - Google Patents

Reovirus que tienen secuencias modificadas Download PDF

Info

Publication number
ES2548442T3
ES2548442T3 ES08733587.3T ES08733587T ES2548442T3 ES 2548442 T3 ES2548442 T3 ES 2548442T3 ES 08733587 T ES08733587 T ES 08733587T ES 2548442 T3 ES2548442 T3 ES 2548442T3
Authority
ES
Spain
Prior art keywords
residue
leu
seq
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08733587.3T
Other languages
English (en)
Spanish (es)
Inventor
Matthew C. Coffey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolytics Biotech Inc
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39758956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2548442(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of ES2548442T3 publication Critical patent/ES2548442T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES08733587.3T 2007-03-12 2008-03-11 Reovirus que tienen secuencias modificadas Active ES2548442T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89442507P 2007-03-12 2007-03-12
US894425P 2007-03-12
US98956807P 2007-11-21 2007-11-21
US989568P 2007-11-21
PCT/CA2008/000483 WO2008110004A1 (en) 2007-03-12 2008-03-11 Reoviruses having modified sequences

Publications (1)

Publication Number Publication Date
ES2548442T3 true ES2548442T3 (es) 2015-10-16

Family

ID=39758956

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08733587.3T Active ES2548442T3 (es) 2007-03-12 2008-03-11 Reovirus que tienen secuencias modificadas

Country Status (16)

Country Link
US (5) US7803385B2 (enExample)
EP (2) EP2132315B1 (enExample)
JP (1) JP5577103B2 (enExample)
KR (1) KR101647843B1 (enExample)
CN (1) CN103710359A (enExample)
AR (1) AR066395A1 (enExample)
AU (1) AU2008226291B2 (enExample)
CA (1) CA2678721C (enExample)
DK (1) DK2132315T3 (enExample)
ES (1) ES2548442T3 (enExample)
IL (4) IL200353A (enExample)
MX (2) MX2009009598A (enExample)
SG (1) SG191602A1 (enExample)
TW (1) TW200904979A (enExample)
WO (1) WO2008110004A1 (enExample)
ZA (1) ZA200905951B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
JP5577103B2 (ja) 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス
EP2211880A4 (en) * 2007-10-22 2012-11-14 Oncolytics Biotech Inc TREATMENT PROCEDURE FOR PROLIFERATIVE DISEASES
TW200951143A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Modulating interstitial pressure and oncolytic viral delivery and distribution
US8470312B2 (en) * 2008-05-27 2013-06-25 Oncolytics Biotech, Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
EP2304024A2 (en) * 2008-06-26 2011-04-06 Biomune Company Avian reoviridae
FR2939807B1 (fr) * 2008-12-11 2010-12-17 Biomerieux Sa Nouveau reovirus isole, procedes et kits de detection
CA2776386C (en) * 2009-10-02 2018-02-27 The Trustees Of Columbia University In The City Of New York Piscine reovirus immunogenic compositions
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
MX337348B (es) * 2011-04-29 2016-02-29 Oncolytics Biotech Inc Metodos para purificar virus utilizando cromatografia de permeacion en gel.
WO2015070323A1 (en) 2013-11-15 2015-05-21 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
US9660989B1 (en) 2014-01-31 2017-05-23 Google Inc. Internet-wide identity management widget
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis
WO2019237063A1 (en) * 2018-06-07 2019-12-12 Emory University Modified reoviruses, particles, and uses in treating proliferative disorders
KR102401077B1 (ko) 2019-01-25 2022-05-24 바이로큐어 주식회사 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2020227245A1 (en) * 2019-05-03 2020-11-12 Kansas State University Research Foundation Immunogenic compositions for novel reassortant mammalian ortheovirus from pigs
WO2022139490A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 변형 레오바이러스 및 이의 용도
EP4268837A4 (en) * 2020-12-22 2025-05-07 Virocure, Inc. NEW MODIFIED REOVIRUS AND ITS USE
US20250154204A1 (en) * 2021-09-24 2025-05-15 Virocure, Inc. Novel reovirus-based vaccine platform and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
DK2189162T3 (da) * 2000-11-09 2014-02-03 Oncolytics Biotech Inc Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
EP1339736A2 (en) * 2000-12-01 2003-09-03 University Of Ottawa Oncolytic virus
DK2253701T3 (da) 2001-03-16 2014-10-20 Oncolytics Biotech Inc Fremgangsmåde til ekstraktion af en virus fra en cellekultur
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
CA2571844A1 (en) 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing minus-strand rna virus
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
WO2008009115A1 (en) 2006-07-18 2008-01-24 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
JP5577103B2 (ja) 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス
US8470312B2 (en) * 2008-05-27 2013-06-25 Oncolytics Biotech, Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
WO2012075379A2 (en) * 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CN103269716B (zh) * 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂

Also Published As

Publication number Publication date
DK2132315T3 (en) 2015-10-19
US20110020288A1 (en) 2011-01-27
KR101647843B1 (ko) 2016-08-11
US10039827B2 (en) 2018-08-07
EP2132315A4 (en) 2011-10-05
US10596260B2 (en) 2020-03-24
EP2952583A1 (en) 2015-12-09
MX346950B (es) 2017-04-06
US7803385B2 (en) 2010-09-28
EP2132315B1 (en) 2015-07-15
KR20090125103A (ko) 2009-12-03
IL200353A0 (en) 2011-08-01
US20200237917A1 (en) 2020-07-30
US8691241B2 (en) 2014-04-08
CN103710359A (zh) 2014-04-09
AU2008226291A2 (en) 2009-10-08
TW200904979A (en) 2009-02-01
AU2008226291B2 (en) 2014-01-16
US11246930B2 (en) 2022-02-15
AR066395A1 (es) 2009-08-19
HK1132761A1 (en) 2010-03-05
IL200353A (en) 2017-07-31
US20140186301A1 (en) 2014-07-03
CA2678721C (en) 2018-02-13
SG191602A1 (en) 2013-07-31
MX2009009598A (es) 2009-09-21
JP5577103B2 (ja) 2014-08-20
IL221701A0 (en) 2012-10-31
US20080226602A1 (en) 2008-09-18
US20090035278A2 (en) 2009-02-05
JP2010520758A (ja) 2010-06-17
ZA200905951B (en) 2010-11-24
CA2678721A1 (en) 2008-09-18
WO2008110004A1 (en) 2008-09-18
IL221702A0 (en) 2012-10-31
IL221700A0 (en) 2012-10-31
EP2132315A1 (en) 2009-12-16
US20180344853A1 (en) 2018-12-06
AU2008226291A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
Shamoo et al. Crystal structure of the two RNA binding domains of human hnRNP A1 at 1.75 Å resolution
Carlson et al. Lack of Borrelia burgdorferi DNA in synovial samples from patients with antibiotic treatment–resistant Lyme arthritis
Bax et al. X-ray analysis of βB2-crystallin and evolution of oligomeric lens proteins
Beall et al. A Drosophila protein homologous to the human p70 Ku autoimmune antigen interacts with the P transposable element inverted repeats.
Walter et al. Molecular cloning and sequence of cDNA encoding polyoma medium tumor antigen-associated 61-kDa protein.
Fan et al. Structural basis of diverse sequence-dependent target recognition by the 8 kDa dynein light chain
Adams et al. Binding of myosin I to membrane lipids
Weiss et al. Comparative sequence analysis of the complete human sarcomeric myosin heavy chain family: implications for functional diversity
Steinert et al. Keratin intermediate filament structure: crosslinking studies yield quantitative information on molecular dimensions and mechanism of assembly
Bardele Functional and phylogenetic aspects of the ciliary membrane: a comparative freeze-fracture study
Weekers et al. Sequence variations in small-subunit ribosomal RNAs of Hartmannella vermiformis and their phylogenetic implications.
Ono et al. Production and characterization of recombinant human Ku antigen
Ruiz Carrillo et al. Structure of human Rack1 protein at a resolution of 2.45 Å
Yoshida et al. Translocation of HSP27 and MKBP in ischemic heart
Glele‐Kakai et al. Epidemiological studies of spectrin mutations related to hereditary elliptocytosis and spectrin polymorphisms in Benin
Antao et al. MHC class I genes of the channel catfish: sequence analysis and expression
Romac et al. The U1 small nuclear ribonucleoprotein (snRNP) 70K protein is transported independently of U1 snRNP particles via a nuclear localization signal in the RNA-binding domain
ES2336657T3 (es) Acidos nucleicos para la identificacion de hongos y procedimientos para usarlos.
VAN KEULEN et al. A three nucleotide signature sequence in small subunit rRNA divides human Giardia in two different genotypes
Nikolakaki et al. RNA association or phosphorylation of the RS domain prevents aggregation of RS domain-containing proteins
CA2195629A1 (en) Src sh3 binding peptides and methods of isolating and using same
Yamanaka et al. Cloning and sequence analysis of the hemagglutinin gene of the virulent strain of rinderpest virus
Poyarkov et al. Phylogeography of the Siberian newt Salamandrella keyserlingii by mitochondrial DNA sequence analysis
Yu et al. Phylogeny and evolution of the Drosophila nasuta subgroup based on mitochondrial ND4 and ND4L gene sequences
Jackson et al. The extra segments of sequence in rat leucocyte common antigen (L-CA) are derived by alternative splicing of only three exons and show extensive O-linked glycosylationt